Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancerpatients

Barros Filho, M. C; Katayama, M. L. H; Brentani, H; Abreu, A. P. S; Barbosa, E. M; Oliveira, C. T; Góes, J. C. S; Brentani, M. M; Folgueira, M. A. A. K.
Braz. j. med. biol. res ; 43(12): 1225-1231, Dec. 2010. ilus, tab
Artículo en Inglés | LILACS | ID: lil-568999

Documentos relacionados

  1. Bacteria in tumors "hit the road" together.
  2. Deciphering breast cancer: from biology to the clinic.
  3. Estrogen receptor gets a grip on RNA.
  4. Homologous recombination deficiency reflects the heterogeneity and monitoring treatment response for patients with breast cancer.
  5. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
  6. Multi-omic machine learning predictor of breast cancer therapy response.
  7. Development of a breast cancer prognostic model based on vesicle-mediated transport-related genes to predict immune landscape and clinical drug therapy.
  8. Estimating clinical risk in gene regions from population sequencing cohort data.
  9. Cooperative driver pathways discovery by multiplex network embedding.
  10. The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.